Here are the 10-K annual reports from Oramed Pharmaceuticals Inc. (ORMP) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ORMP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ORMP filings page.
Oramed Pharmaceuticals Inc. files its annual report outlining a major strategic evolution. The company remains focused on oral delivery of proteins, including an oral insulin capsule, and plans a 60‑patient U.S. clinical trial in 2026 targeting high‑responder diabetes subpopulations via OraTech.
Oramed terminated its joint venture with HTIT, then transferred its POD oral delivery platform and OraTech equity to Lifeward in exchange for up to 49.99% fully diluted equity, warrants and revenue sharing on ReWalk Personal Exoskeleton sales, plus senior secured convertible notes. It also deploys significant capital into healthcare equities, royalties, and loans, including sizable stakes in Alpha Tau, Nano Dimension, Scilex‑linked notes and royalties, a new Corner Ally Ventures fund commitment, and several Israeli real estate and project‑finance loans, while warning that these concentrated investments and counterparties’ performance pose material risks.